|
Product | Quantum (Rs. Cr) | Long Term Rating | Short Term Rating |
Bank Loan Ratings | 16.25 | ACUITE BB+ | Reaffirmed | Issuer not co-operating* | - |
Bank Loan Ratings | 2.00 | - | ACUITE A4+ | Reaffirmed | Issuer not co-operating* |
Total Outstanding | 18.25 | - | - |
Rating Rationale |
Acuité has reaffirmed the long term rating of ‘ACUITE BB+’ (read as ACUITE double B plus) and the short term rating of ‘ACUITE A4+’ (read as ACUITE A four plus) on the Rs.18.25 Crore bank facilities of Ion Healthcare Private Limited. The rating continues to be flagged as “Issuer Not-Cooperating” and is based on the best available information. |
About the Company |
Ion Healthcare Private Limited (IHPL) was incorporated in 2004 and subsequently acquired by Mr. B. K. Agarwal, Mr. Sanjeev Agarwal and Mrs. Vaishali Agarwal in 2014 presently being controlled and managed by Sh. Atul Kumar Agrawal & Sh. Leela Krishna Varshney in Baddi, Himachal Pradesh. The company is engaged in the manufacturing of generic drugs, ointments, ophthalmic drops, syrups, injections and among other pharmaceutical products. The company has an installed capacity of 430 million tablets, 135 million capsules, 18 million ointments and 25 million syrups. |
About the Group |
Scott Edil Group (SEG) comprises of Scott Edil Pharmacia Limited (SEPL), Ion Healthcare Private Limited (IHPL) and Scott Edil Advance Research Laboratories & Education Limited (SEARLE). The group is promoted by Mr. B.K. Agarwal, Mr. Sanjeev Agarwal and Mrs. Vaishali Agarwal. The group is engaged in the manufacturing of generic drugs, eye drops, syrups, capsules, tablets and medicinal ointments with it’s a manufacturing facilities at Baddi, Himachal Pradesh. The group markets its products under 485 brands through a pan-India distribution network of authorized distributors and stockiest. SEG also undertakes contract manufacturing for marquee players like Abbott Healthcare Limited, Alembic Pharmaceuticals Limited and Lupin Limited among others and also caters to central government institutions. Further, the group also caters to the export market to countries like Sri Lanka, Turkey, Jordan, Afghanistan, Iran, and Panama among others. |
Unsupported Rating |
Not Applicable |
Non-cooperation by the issuer/borrower: |
Acuité has been requesting for data, information and undertakings from the rated entity for conducting surveillance & review of the rating. However, the issuer/borrower failed to submit such information before the due date. |
Limitation regarding information availability: |
The rating is based on information available from sources other than the issuer/borrower (in the absence of information provided by the issuer/borrower). Acuité endeavored to gather information about the entity / industry from the public domain. Therefore, Acuité cautions lenders and investors regarding the use of such information, on which the indicative credit rating is based. |
Rating Sensitivity |
"No information provided by the issuer / available for Acuite to comment upon." |
Liquidity Position |
"No information provided by the issuer / available for Acuite to comment upon." |
Outlook |
Not Applicable |
Other Factors affecting Rating |
None |
Particulars | Unit | FY 22 (Actual) | FY 21 (Actual) |
Operating Income | Rs. Cr. | 50.05 | 46.15 |
PAT | Rs. Cr. | 0.07 | 0.25 |
PAT Margin | (%) | 0.14 | 0.54 |
Total Debt/Tangible Net Worth | Times | 1.64 | 1.56 |
PBDIT/Interest | Times | 2.04 | 2.06 |
Status of non-cooperation with previous CRA |
Not Applicable |
Any other information |
None |
Applicable Criteria |
• Manufacturing Entities: https://www.acuite.in/view-rating-criteria-59.htm • Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm • Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm |
Note on Complexity Levels of the Rated Instrument |
In order to inform the investors about complexity of instruments, Acuité has categorized such instruments in three levels: Simple, Complex and Highly Complex. Acuite’ s categorisation of the instruments across the three categories is based on factors like variability of the returns to the investors, uncertainty in cash flow patterns, number of counterparties and general understanding of the instrument by the market. It has to be understood that complexity is different from credit risk and even an instrument categorized as 'Simple' can carry high levels of risk. For more details, please refer Rating Criteria “Complexity Level Of Financial Instruments” on www.acuite.in. |
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
|
Contacts |
|
|
About Acuité Ratings & Research |
© Acuité Ratings & Research Limited. All Rights Reserved. | www.acuite.in |